{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"249"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"295"}],"units":"Participants"}],"description":"An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.","groups":[{"description":"Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.","id":"OG000","title":"Ixazomib + Lenalidomide + Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set: all participants who were enrolled into the study and who receive at least one dose of any drug used in IRd therapy (i.e. ixazomib, lenalidomide, or dexamethasone)","reportingStatus":"POSTED","timeFrame":"Up to 36 months as a maximum","title":"Number of Participants Reporting One or More Treatment-Emergent AEs (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}